BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Talquetamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Talquetamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06505369-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06505369)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Bispecific T-
 cell Redirectors as Part of First Line Treatment in Transplant Eligible Mu
 ltiple Myeloma Patients\nEstimated primary completion: November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06505369
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827860-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06827860)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Subcutaneous 
 Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06827860
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499323-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270320
DTEND;VALUE=DATE:20270321
SUMMARY:Talquetamab: Phase na readout est. (NCT07499323)
DESCRIPTION:Talquetamab\, phase na.\nStudy: Talquetamab in Patients With Re
 fractory Generalized Myasthenia Gravis\nEstimated primary completion: 20 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talquetama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 499323
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04108195-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Talquetamab: Phase 1 readout est. (NCT04108195)
DESCRIPTION:Talquetamab\, phase 1\, Multiple Myeloma.\nStudy: A Study of Su
 bcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redi
 rection Antibodies for the Treatment of Participants With Multiple Myeloma
 \nEstimated primary completion: 7 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04108195
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04634552-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Talquetamab: Phase 2 readout est. (NCT04634552)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ta
 lquetamab in Participants With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04634552
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093554-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Talquetamab: Phase 1 readout est. (NCT07093554)
DESCRIPTION:Talquetamab\, phase 1\, Multiple Myeloma.\nStudy: Cilta-Talq Fu
 sion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by C
 iltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Mye
 loma\nEstimated primary completion: 1 July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07093554
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07032714-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Talquetamab: Phase 1 readout est. (NCT07032714)
DESCRIPTION:Talquetamab\, phase 1\, Multiple Myeloma.\nStudy: Mezigdomide a
 nd Talquetamab in Relapsed and Refractory Multiple Myeloma\nEstimated prim
 ary completion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/talquetamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07032714
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455320-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Talquetamab: Phase 3 readout est. (NCT05455320)
DESCRIPTION:Talquetamab\, phase 3\, Multiple Myeloma.\nStudy: A Study Compa
 ring Talquetamab in Combination With Daratumumab or in Combination With Da
 ratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalido
 mide and Dexamethasone in Participants With Multiple Myeloma That Returns 
 After Treatment or is Resistant to Treatment\nEstimated primary completion
 : 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talqu
 etamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05455320
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348108-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Talquetamab: Phase 1 readout est. (NCT06348108)
DESCRIPTION:Talquetamab\, phase 1\, Multiple Myeloma.\nStudy: Talquetamab i
 n Combination With Iberdomide and Dexamethasone for Relapsed or Refractory
  Multiple Myeloma\nEstimated primary completion: 31 July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06348108
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05972135-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Talquetamab: Phase 2 readout est. (NCT05972135)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Outpatient Ad
 ministration of Teclistamab or Talquetamab for Multiple Myeloma\nEstimated
  primary completion: August 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/talquetamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05972135
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550895-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270826
DTEND;VALUE=DATE:20270827
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06550895)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ci
 ltacabtagene Autoleucel and Talquetamab for the Treatment of Participants 
 With High-Risk Multiple Myeloma\nEstimated primary completion: 26 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06550895
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06066346-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06066346)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ta
 lquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Ce
 ll Therapy\nEstimated primary completion: October 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06066346
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06461988-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06461988)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Talquetamab &
  Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06461988
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07657312-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Talquetamab: Phase 2 readout est. (NCT07657312)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Infliximab fo
 r Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab 
 Therapy in Patients With Relapsed or Refractory Myeloma\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/talquetamab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07657312
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353022-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06353022)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Minimal Resid
 ual Disease-based Strategy With T-Cell Redirector After Treatment With Dar
 atumumab\, Bortezomib\, Lenalidomide\, and Dexamethasone (D-VRd) in Newly 
 Diagnosed Multiple Myeloma\nEstimated primary completion: 26 April 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06353022
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Talquetamab: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / D
 SMM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 Se
 ptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talquet
 amab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05695508
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06100237-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06100237)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab i
 n Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinica
 l and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)\nEstima
 ted primary completion: 31 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06100237
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107529-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Talquetamab: Phase 2 readout est. (NCT07107529)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Study for Fra
 il Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab
  With Teclistamab or Talquetamab.\nEstimated primary completion: April 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07107529
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581704-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Talquetamab: Phase 1 readout est. (NCT07581704)
DESCRIPTION:Talquetamab\, phase 1\, Multiple Myeloma.\nStudy: Sirolimus Pre
 -conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody E
 fficacy in Multiple Myeloma\nEstimated primary completion: 1 June 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07581704
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993675-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06993675)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Engaging T-ce
 lls to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With T
 alquetmab and Teclistamab (ROTATE)\nEstimated primary completion: August 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06993675
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720843-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Talquetamab: Phase 1 readout est. (NCT07720843)
DESCRIPTION:Talquetamab\, phase 1\, Multiple Myeloma.\nStudy: TAlquetamab a
 nd BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)\
 nEstimated primary completion: March 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07720843
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029776-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Talquetamab: Phase 2 readout est. (NCT07029776)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: MMulti-Immune
  HR\; Multi-Target Immunotherapy for High-Risk Multiple Myeloma\nEstimated
  primary completion: 1 April 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/talquetamab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07029776
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Di
 fferent Sequences of Cilta-cel\, Talquetamab in Combination With Daratumum
 ab and Teclistamab in Combination With Daratumumab Following Induction Wit
 h Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone in Participant
 s With Standard-risk Newly Diagnosed Multiple Myeloma\nEstimated primary c
 ompletion: 2 September 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/talquetamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05552222-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Talquetamab: Phase 3 readout est. (NCT05552222)
DESCRIPTION:Talquetamab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Te
 clistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Ta
 lquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Par
 ticipants With Newly Diagnosed Multiple Myeloma\nEstimated primary complet
 ion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 alquetamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05552222
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740486-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Talquetamab: Phase 3 readout est. (NCT07740486)
DESCRIPTION:Talquetamab\, phase 3\, Multiple Myeloma.\nStudy: A Study Compa
 ring Treatment With Teclistamab and Talquetamab Versus Daratumumab and Len
 alidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who
  Still Have Detectable Disease\nEstimated primary completion: June 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07740486
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649525-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Talquetamab: Phase 3 readout est. (NCT07649525)
DESCRIPTION:Talquetamab\, phase 3\, Multiple Myeloma.\nStudy: Personalising
  Treatment for Myeloma Patients Based on Initial Response to NHS Treatment
  and Their Overall Fitness Level\nEstimated primary completion: June 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07649525
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887984-3135@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Talquetamab: Phase 2/3 readout est. (NCT07887984)
DESCRIPTION:Talquetamab\, phase 2/3\, Multiple Myeloma.\nStudy: Comparing B
 ispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly 
 Diagnosed\, Standard Risk Multiple Myeloma\nEstimated primary completion: 
 1 August 2033. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talque
 tamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07887984
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
